Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
  Allergy & asthma
  Biotechnology
  Communicable diseases
  Drugs & drug processes
  Genetic engineering
  Genomics
  Health & ageing
  Health & poverty
  Health & special needs
  Health systems & management
  Major diseases
  Medical research
  Molecular biology
  Neuroscience
  Public health
  Rare & orphan diseases
  Other
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belgium
  Benin
  Brazil
  Bulgaria
  Canada
  Chile
  China
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


This page was published on 16/06/2009
Published: 16/06/2009

   Success Stories

Last Update: 16-06-2009  
Related category(ies):
Health & life sciences

 

Add to PDF "basket"

Malaria: tracking a serial-killer

There are up to 500 million cases of malaria each year. According to the World Health Organisation, severe malaria kills one child every minute in Sub-Saharan Africa. It is a desperate situation that has lead to cooperative research between Africa and Europe, which may yield a more efficient and effective treatment against malaria in small children.

Video in QuickTime format:  ar  de  en  es  fr  it  pt  ru  (22 MB)

The parasites responsible for the disease are normally transmitted through the bite of a female mosquito. The parasites enter the blood stream and begin to reproduce in the liver. After destroying the liver cells they enter the blood stream again, this time in very high numbers. At this stage symptoms such as fever appear. The parasites then destroy red blood cells, causing anemia, among other effects.

It is not until the age of five that the human body has developed partial immunity to malaria, making young children almost defenceless against the disease. Unless treated, sufferers of malaria will experience a long phase of vomiting before falling into a coma. At this point administering medication becomes complicated and can only be done intravenously.

In Africa severe malaria will usually be treated with quinine. At the moment trails are under way for an alternative treatment with intravenous artesunate, an artemisinin derivative. It is the aim of an Afro-European research project (funded by the EDCTP) to investigate whether this derivative is more effective than quinine.

Trials are taking place at the Albert Schweitzer Hospital in Gabon, Central Africa, where up to 30 percent of the emergency admissions involving children will lead to a diagnosis of malaria. Blood samples are taken every six hours from patients being treated with the new medication. Experts can then estimate how effective the treatment is by calculating the change in density of parasites in the blood. They can also observe the treatment to assure that there are no adverse side-effects.

Another aim of the research is to improve the treatment administration, so that a child can be treated in three days with just a single dosage each day.

The data from these trials are then sent to the Institute for Tropical Diseases at Tuebingen University in Germany. Biologists study the malaria parasites and the effect upon them by various drugs at various doses. Preliminary results appear positive for the treatment with intravenous artesunate. The studies show that a single daily dose for three days destroys the parasites effectively.

For the researchers in Gabon it is also important to visit the children treated with the artesunate after their hospitalisation for further monitoring and to be sure that the fever has not returned, thus evaluating the efficiency of the treatment.

The researchers visit a five year old child from the village Komi who was treated with intravenous artesunate one month earlier. About four in five children from Komi will suffer malaria before the age of five. The medical examinations show that the child is indeed on the way to a full recovery. The research indicates that the artesunate treatment works faster than quinine and, as far as is known, has fewer side effects.

Although this research could lead to a better method for combating severe malaria in small children, prevention remains a key factor in high risk areas of Africa. As well as improved medical treatment, the simple distribution of mosquito nets and their proper installation can also safe lives.

Further information

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Futuris, the European research programme - on Euronews. The video on this page was prepared in collaboration with Euronews for the Futuris programme.

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center